The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
RU58841 should be applied directly to the scalp, ideally once a day, a few hours before bed. Some users experienced side effects like shedding and systemic issues when using RU58841 and Minoxidil together, while others reported no side effects when using RU58841 alone.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
The user shared progress after one year of using Minoxidil, rosemary oil, and dermarolling for hair loss, noting fuller hair despite some scalp exposure. Another user inquired about the dermarolling process and frequency.
Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.
A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.
User shared progress pictures after 3 months of using Minoxidil 5% and dermarolling, noting significant shedding but positive results. They plan to continue and may add finasteride.
A user is attempting to recover from severe hair loss using 1.25mg finasteride, 5mg topical minoxidil twice daily, pyrilutamide for a month, RU58841 for two weeks, and weekly microneedling at 1.5mm. They have seen new hair growth after two months and plan to continue the treatment for a year with the hope of regrowing enough hair for a transplant.